Aspirin (acetylsalicylic acid; ASA) is one of the most commonly used drugs, Studies have showed that low dose ASA can reduce cardiovascular events by irreversibly binding to cyclooxygenase and inhibiting platelet aggregation. However, ASA has not prevented all patients from cardiovascular events [1]. Ackerman and Newman were the first to describe the phenomenon of Aspirin resistance (AR) in 1990, named "incomplete antiplatelet effect of aspirin". Afterwards, in the last two decades, several studies have demonstrated that some people do not respond to low dose aspirin as an anti-platelet [2].